Table 4. P-values of top four best pathways with both common and rare variants associated with EOMI.
| Name of pathway | Pyrimidine metabolism | Glycosaminoglycan degradation | Metabolic pathway | mRNA surveillance pathway |
|---|---|---|---|---|
| Number of genes | 101 | 14 | 897 | 90 |
| EA | ||||
| SFPCA | 1.70E-05 | 1.00E-04 | 4.50E-04 | 9.00E-04 |
| FPCA | 3.30E-04 | 9.10E-04 | 7.30E-03 | 8.76E-03 |
| LCT/LCT | 4.00E-03 | 2.17E-01 | 2.60E-02 | 6.83E-02 |
| QT/QT | 2.15E-02 | 8.80E-02 | 7.94E-03 | 5.70E-02 |
| DT/DT | 1.95E-01 | 6.00E-03 | 1.33E-01 | 4.80E-02 |
| WSS/Fisher exact | 7.40E-02 | 1.10E-02 | 5.80E-02 | 1.17E-01 |
| VT/Fisher exact | 2.90E-02 | 5.90E-02 | 8.60E-02 | 3.45E-02 |
| CMC/Fisher exact | 3.73E-02 | 7.40E-02 | 6.20E-02 | 1.06E-01 |
| GSEA | 1.29E-02 | 7.30E-02 | 6.22E-02 | 5.15E-02 |
| SKAT | 2.40E-03 | 1.60E-03 | 3.34E-02 | 6.33E-02 |
| CMC | 1.30E-01 | 1.59E-01 | 1.52E-01 | 2.21E-02 |
| PCA | 1.11E-02 | 1.30E-03 | 1.46E-02 | 1.37E-02 |
| AA | ||||
| SFPCA | 5.60E-04 | 2.80E-04 | 9.40E-05 | 5.90E-04 |
| FPCA | 8.70E-03 | 7.70E-03 | 7.30E-02 | 4.20E-03 |
| LCT/LCT | 2.61E-02 | 8.00E-03 | 2.20E-02 | 9.60E-03 |
| QT/QT | 6.08E-02 | 6.00E-03 | 1.41E-01 | 4.02E-01 |
| DT/DT | 1.52E-01 | 1.00E-03 | 1.07E-01 | 1.49E-01 |
| WSS/Fisher exact | 8.80E-02 | 1.70E-02 | 4.60E-02 | 5.36E-03 |
| VT/Fisher exact | 9.00E-03 | 6.00E-02 | 3.78E-01 | 1.80E-02 |
| CMC/Fisher exact | 1.50E-02 | 3.25E-01 | 4.80E-02 | 3.00E-02 |
| GSEA | 1.91E-02 | 4.18E-01 | 5.57E-01 | 6.65E-02 |
| SKAT | 1.89E-02 | 4.91E-02 | 2.30E-02 | 8.90E-03 |
| CMC | 3.60E-02 | 8.80E-02 | 4.19E-03 | 3.50E-02 |
| PCA | 1.33E-02 | 1.02E-02 | 1.75E-01 | 7.00E-03 |
Abbreviations: AA, African origin; CMC, combined multivariate and collapsing; DT, de-correlation test; EE, European origin; EOMI, early-onset myocardial infarction; FPCA, functional principal component analysis; LCT, linear combination test; QT, quadratic test; SFPCA, smoothed functional principal component analysis; VT, variable-threshold; WSS, weighted sum.